Radiation recall dermatitis triggered by sorafenib after radiation therapy for hepatocellular carcinoma.
- Author:
Gwi Eon KIM
1
;
Hee Sung SONG
;
Ki Jung AHN
;
Young Suk KIM
Author Information
- Publication Type:Case Report
- Keywords: Sorafenib; Radiotherapy; Radiation recall dermatitis; Hepatocellular carcinoma
- MeSH: Adult; Carcinoma, Hepatocellular*; Exanthema; Humans; Neoplasm Metastasis; Pruritus; Radiodermatitis*; Radiotherapy; Skin; Thoracic Wall
- From:Radiation Oncology Journal 2017;35(3):289-294
- CountryRepublic of Korea
- Language:English
- Abstract: Sorafenib is widely used for unresectable and metastatic hepatocellular carcinomas. Radiation recall dermatitis (RRD) is an acute inflammatory reaction confined to previously irradiated skin that occurs after the administration of certain drugs. RRD after sorafenib treatment is rare; five cases have been reported thus far. We describe a 44-year-old man irradiated for chest wall bone metastasis from hepatocellular carcinoma. Eight days after radiotherapy completion, systemic therapy for metastatic hepatocellular carcinoma was initiated with sorafenib treatment. Eleven days after starting sorafenib, the patient complained of erythematous rash with pruritus in the chest wall, in a location consistent with the previous radiation field. Sorafenib was continued at the same dose, despite the RRD. The skin reaction subsided over the next 2 weeks without any medical intervention.
